# Nuclide record nct04919226 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct04919226/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct04919226", "NCT04919226" ;
  schema:name "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE"@en ;
  schema:alternateName "COMPOSE"@en ;
  schema:description "A phase 3 trial of 177Lu-edotreotide, Temozolomide, Capecitabine, Everolimus, Leucovorin (folinic acid) and Oxaliplatin in neuroendocrine tumours, run by ITM Solucin GmbH, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct04919226/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04919226> ;
  nuclide:status "active" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/grade-3-net/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/> ;
  nuclide:drugs <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/drugs/temozolomide/>, <https://nuclide.cc/drugs/capecitabine/>, <https://nuclide.cc/drugs/everolimus/> ;
  nuclide:companies <https://nuclide.cc/companies/itm/> .